Cargando…
Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report
Acquired pure red cell aplasia (aPRCA) is a kind of anemia characterized by severe reticulocytopenia and reduced bone marrow erythroblastic cells. For patients who are refractory to the first-line therapy (cyclosporin A with/without glucocorticoids), second-line therapy is considered less effective....
Autores principales: | Huang, Yuzhou, Jiang, Xianyong, Han, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372523/ https://www.ncbi.nlm.nih.gov/pubmed/32733663 http://dx.doi.org/10.1177/2040620720940144 |
Ejemplares similares
-
Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study
por: Yang, Yuan, et al.
Publicado: (2023) -
Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
por: Gangat, Naseema, et al.
Publicado: (2022) -
Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab
por: Tendas, Andrea, et al.
Publicado: (2016) -
Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin
por: Padhi, Somanath, et al.
Publicado: (2021) -
Acquired pure red cell aplasia: updated review of treatment
por: Sawada, Kenichi, et al.
Publicado: (2008)